Blog

80 Mile plc (LSE:80M) has amended the joint venture arrangements covering its Jameson liquid hydrocarbon project in Greenland, extending deadlines for the first two exploration wells to 31 December 2028.

Under an extension letter, March GL Company will transfer its rights and obligations under the joint venture to Greenland Energy Company as part of an internal reorganisation.

Greenland Energy Company will assume responsibility for obtaining and maintaining the permits required for the Jameson projects and will bear the associated costs.

80 Mile to Receive £500,000 Cash Payment

As part of the revised arrangements, 80 Mile will receive a £500,000 cash payment upon signing the extension letter.

The deadlines for drilling both the first and second exploration wells have been moved to 31 December 2028.

The revised terms provide additional time for the joint venture to progress permitting and other work associated with the Jameson project.

Company Cites Greenland Strategic Developments

80 Mile also referred to a new trilateral security and defence agreement involving Greenland, Denmark and the United States.

The company said it believes increased international cooperation could support investor confidence and investment in Greenland’s energy and critical mineral sectors.

However, decisions regarding permits for the Jameson project remain with the relevant Greenlandic authorities and are subject to applicable environmental and community requirements.

About 80 Mile

80 Mile is an exploration and development company with mining and liquid hydrocarbon projects in Greenland.

Through its Jameson joint venture, the company is pursuing exploration activities in East Greenland. Its wider portfolio includes projects targeting energy and mineral resources in the country.

On the Beach Group (LSE:OTB) said adjusted pre-tax profit for the 2026 financial year is expected to be between £22 million and £23 million, placing the result in the upper half of its previous guidance range.

The online package holiday provider reported its fifth consecutive year of record total transaction value, with bookings increasing 9% to £1.3 billion.

The group ended the financial year debt-free and with approximately £60 million in cash.

Shareholder Returns Total Around £67 Million Over Two Years

On the Beach said it returned approximately £67 million to shareholders through dividends and share buybacks over the past two years.

The company reported continued booking growth during Summer 2026 and into the beginning of the 2027 financial year.

Bookings during the most recent eight-week period increased 17%, while bookings from repeat customers rose 18%.

The company attributed the performance to factors including investment in technology, expansion of its product range and its brand activities.

FY27 Profit Guidance Set at £28-35 Million

On the Beach expects adjusted pre-tax profit of between £28 million and £35 million for FY27.

The guidance represents an increase from the £22 million to £23 million expected for FY26, although the FY27 figure remains a company forecast and is subject to future trading conditions.

The group continues to expand its operations across beach and city holidays, the Republic of Ireland and cruise products.

On the Beach also identified macroeconomic conditions and geopolitical developments in travel destinations as factors affecting the operating environment.

About On the Beach Group

On the Beach Group is an online package holiday provider serving customers in the UK and Republic of Ireland.

The company offers beach, city and cruise holidays and operates through an asset-light business model supported by its proprietary technology platform and relationships with travel suppliers.

Poolbeg Pharma (LSE:POLB) has reported interim safety data from its ongoing TOPICAL clinical trial of POLB 001, with an independent review recommending that the study continue without changes.

The trial is evaluating POLB 001 as a preventative treatment for Cytokine Release Syndrome in patients with relapsed or refractory multiple myeloma receiving the bispecific antibody teclistamab.

Following the safety review, patient recruitment will continue at participating UK clinical sites, while Poolbeg plans to activate additional centres.

Independent Review Recommends Trial Continue Without Changes

The interim review assessed safety data generated during the ongoing TOPICAL study.

Based on the data reviewed, the independent assessment recommended that the trial proceed without modifications.

The update relates to safety and does not establish the efficacy of POLB 001 in preventing Cytokine Release Syndrome. The clinical trial remains ongoing.

Poolbeg Continues POLB 001 Development

POLB 001 is being developed to prevent Cytokine Release Syndrome, a complication that can occur with certain cancer immunotherapies.

Poolbeg is evaluating whether preventing the condition could support the use of treatments such as bispecific antibodies in a broader range of clinical settings.

The company said it intends to share emerging data from the programme with prospective partners as development progresses.

Poolbeg Pharma Pipeline

Poolbeg Pharma is a clinical-stage biopharmaceutical company developing treatments in cancer immunotherapy and other therapeutic areas.

POLB 001 is its lead clinical asset and is being evaluated for the prevention of Cytokine Release Syndrome associated with cancer immunotherapies.

The company’s development pipeline also includes an oral GLP-1 programme targeting obesity.

Scancell Holdings (LSE:SCLP) has secured a loan facility of up to US$25 million from funds managed by BlackRock to support the planned Phase 3 development of its iSCIB1+ melanoma programme.

The debt financing is being arranged alongside Scancell’s proposed merger with Neuphoria Therapeutics and planned Nasdaq listing.

The facility includes partially convertible tranches and warrants and is secured over group assets. The financing therefore creates repayment obligations and could result in future dilution through its convertible elements and warrants.

The arrangements are subject to conditions including shareholder approval and completion of the proposed U.S. listing transactions.

Initial US$7 Million Drawdown Planned

Scancell plans to draw an initial US$7 million from the facility following an upcoming extraordinary general meeting.

A further US$8 million is expected to become available following completion of the U.S. listing transactions and the opening of the first global Phase 3 clinical trial site for iSCIB1+.

The remaining availability under the facility provides Scancell with additional potential debt funding subject to the applicable terms and conditions.

iSCIB1+ Phase 3 Trial Targeted for End of 2026

Scancell is developing iSCIB1+ for advanced melanoma and plans to begin the Phase 3 trial by the end of 2026.

The company has received U.S. Food and Drug Administration Investigational New Drug clearance and approval from the UK’s Medicines and Healthcare products Regulatory Agency for the programme.

Scancell is targeting progression-free survival data from the Phase 3 programme during the second half of 2028.

The company is pursuing a development pathway that could potentially support accelerated approval, although any regulatory outcome remains subject to the clinical results and applicable regulatory processes.

Scancell Develops Cancer Immunotherapies

Scancell is a clinical-stage biotechnology company developing immunotherapies for cancer.

Its pipeline includes iSCIB1+, a DNA ImmunoBody being developed for advanced melanoma, as well as the Moditope-based Modi-1 programme and a GlyMab antibody portfolio. The company also has partnered programmes with Genmab.

EMV Capital (LSE:EMVC) reported net assets of £33.4 million in its interim results, with net asset value per share increasing 145% to £1.20.

The increase was largely attributable to the deconsolidation of diagnostics companies Glycotest and ProAxsis. On an underlying basis, EMV Capital reported a 16% increase in Adjusted NAV per share.

Assets under management stood at £117.5 million as of 30 June 2026.

One-Off Gain Results in £17.8 Million Headline Profit

EMV Capital reported a headline profit of £17.8 million for the period, reflecting a one-off non-cash gain associated with changes in the treatment of portfolio companies.

The group’s core business recorded an underlying loss during the period as EMV Capital continued investing in its infrastructure and portfolio.

The company has been developing AI-enabled infrastructure, expanding recurring-revenue services and syndicating third-party capital as part of its investment platform.

Portfolio Companies Progress Development Programmes

EMV Capital reported developments across several companies in its portfolio during the period.

AMR Bio continued work on its antimicrobial programme ahead of a planned Phase 3 programme, while DeepTech Recycling progressed its plastic-to-oil technology.

SageTech continued development of its anaesthetic gas capture systems, and Sofant advanced its phased-array antenna technology.

Glycotest and ProAxsis, meanwhile, secured additional funding following their deconsolidation and are now operating on independent development paths.

EMV Capital Focuses on Deep Tech, Life Sciences and Sustainability

EMV Capital is a venture capital investment group focused on deep technology, life sciences and sustainability.

The group operates through corporate finance, value creation services and fund management, with portfolio exposure to areas including diagnostics, antimicrobial therapies, advanced recycling, medical gas technologies and communications hardware.

Cobra Resources (LSE:COBR) has reported diamond drilling results from its Blue Rose discovery at the Manna Hill Copper Project in South Australia, with copper-gold-molybdenum mineralisation identified at depths beyond 300 metres.

The company said the drilling identified geological indicators consistent with a porphyry-style system.

Reported intersections include 23 metres grading 0.63% copper in hole MHDD002, including 12.4 metres at 1.01% copper.

MHDD004 Intersects 36 Metres at 0.39% Copper

At MHDD004, Cobra reported an intersection of 36 metres grading 0.39% copper.

The interval included 10 metres grading 0.99% copper, alongside molybdenum mineralisation.

Cobra said the results provide further evidence of a hydrothermal system at Blue Rose, while extending the identified copper-gold-molybdenum mineralisation to depths exceeding 300 metres.

Follow-Up Drilling Programme Underway

Following the diamond drilling results, Cobra has started a slimline reverse circulation drilling programme of up to 6,000 metres across four prospects at the Manna Hill project.

The programme is designed to test strike extensions to the mineralisation identified at Blue Rose and assess additional targets, including Netley Hill and Anabama.

Results from the follow-up campaign will provide further geological information on the extent of the mineral systems being explored across Manna Hill.

Cobra Resources’ South Australian Projects

Cobra Resources is a South Australian mineral exploration and development company focused on the Manna Hill Copper Project and Wudinna Rare Earth Project.

At Manna Hill, the company is exploring for shallow skarn and deeper porphyry-style copper-gold mineral systems within the Nackara Arc copper-gold province.

Halma (LSE:HLMA) has raised its adjusted EBIT margin guidance following first-half trading, while forecasting low double-digit organic revenue growth for the full year.

The FTSE 100 technology group said growth was broad-based across its operations despite economic and geopolitical uncertainty. Halma also reported continued order intake and cash generation during the period.

Adjusted EBIT Margin Guidance Raised

Halma now expects an adjusted EBIT margin of between 23.5% and 24% for the 2027 financial year, compared with previous guidance of approximately 22.7%.

The company expects low double-digit organic revenue growth for the full year.

This includes an approximately five percentage point contribution from its photonics business, where Halma expects organic revenue growth of around 30%.

Halma also said a stronger pound is expected to have a modest negative effect on reported revenue and profit through currency translation.

Acquisition Spending Reaches £515 Million

Halma reported record acquisition spending of £515 million across six transactions as it continued to deploy capital into its portfolio.

The group also completed three disposals, generating approximately £83 million.

Halma operates a decentralised business model, with its individual companies retaining operational autonomy while capital allocation and portfolio decisions are managed at group level.

Halma Operates Across Three Market Sectors

Halma comprises technology businesses operating across safety, environmental and analysis, and healthcare markets.

Its businesses develop products and technologies used in areas including safety and critical infrastructure, environmental monitoring and analysis, and the prevention, diagnosis and treatment of medical conditions.

The group employs more than 9,000 people across more than 20 countries.

System1 Group (LSE:SYS1) has raised its full-year adjusted profit guidance after reporting an increase in profitability during the five months to 31 August 2026.

Adjusted profit before tax increased to £2.1 million from £0.3 million in the corresponding period a year earlier, while revenue rose 11%.

The marketing decision-making platform reported a gross margin of 87% for the period.

Customer Activity and Cost Controls Support Results

System1 said the performance reflected increased engagement from existing customers alongside new business activity.

Costs were also lower in some areas, including salary expenses, although this was partly offset by targeted spending on marketing.

The company has been implementing cost-efficiency measures including workflow standardisation, improvements to its systems and increased use of artificial intelligence and automation.

Full-Year Profit Guidance Raised to £5 Million

Following the five-month performance, System1’s board increased its adjusted profit before tax guidance for the year ending 31 March 2027 by approximately 19% to £5.0 million.

The revised forecast would bring adjusted profit before tax back in line with the level recorded in the 2025 financial year.

System1 did not increase its full-year revenue guidance as part of the update.

About System1 Group

System1 provides a marketing decision-making platform designed to help advertisers assess the potential commercial impact of advertising, innovation and brand ideas by measuring consumer emotion.

The company serves more than 600 clients across 81 markets, including 48 of the world’s 100 largest brands by media spend.